Azithromycin-13C-d3

Description

Azithromycin-13C-d3 is intended for use as an internal standard for the quantification of azithromycin (Item No. 15004) by GC- or LC-MS. Azithromycin is a macrolide antibiotic.1 It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively).2 It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 µM.3 Azithromycin also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg.4 Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.WARNING This product is not for human or veterinary use.

References

[1] M S KANATANI  B J G. The new macrolides. Azithromycin and clarithromycin.[J]. The Western journal of medicine, 1994, 160 1: 31-37.
[2] D GIRARD. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.[J]. Journal of Antimicrobial Chemotherapy, 2005, 56 2: 365-371. DOI: 10.1093/jac/dki241
[3] AHMED MOSTAFA. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.[J]. ACS Applied Energy Materials, 2020. DOI: 10.3390/ph13120443
[4] ANASUYA PATEL. Azithromycin in Combination with Ceftriaxone Reduces Systemic Inflammation and Provides Survival Benefit in a Murine Model of Polymicrobial Sepsis.[J]. ACS Applied Energy Materials, 2018. DOI: 10.1128/aac.00752-18